PrimeRFP SCOUT · Federal Contract Recompete Brief

15F06724F0001366GSK TRAVEL vaccines — Glaxosmithkline LLC

Glaxosmithkline LLC holds $3.0B across 194 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 5 related awards under parent 15F06722A0000187. The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: Unrestricted. PoP ended Dec 31, 2024 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Division 1200

Awarding office

Glaxosmithkline LLC

Recipient

Dec 31, 2024

PoP end

$50K

Obligated

$115K

Potential

325412

NAICS

6515

PSC

Unrestricted

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Contract facts

Unrestricted

Contract number15F06724F0001366

Also listed as15F06722A0000187-15F06724F0001366

AgencyDivision 1200

Awarding officeDivision 1200

Awarding agencyDepartment of Justice (DOJ)

Funding agencyDepartment of Justice (DOJ)

IncumbentGlaxosmithkline LLC

CAGE667E9

UEIFRHTPHMZMX47

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6515

Parent IDIQ / IDV15F06722A0000187

Place of performanceDURHAM NC

Pricing typeFirm Fixed Price

Extent competedCompeted Under SAP

PoP startFeb 27, 2022

PoP end (current)Dec 31, 2024

PoP end (w/ options)Dec 31, 2026

Obligated$50K

Current value$115K

Potential value$115K

GSK TRAVEL VACCINES is a federal Unrestricted award for Division 1200 held by Glaxosmithkline LLC. Estimated value $115K ($50K obligated). Current period of performance ends Dec 31, 2024 (potential Dec 31, 2026). Last award drew 1 bidder. Place of performance: DURHAM NC.

Recompete timing

Public

● Past PoP end (639 days ago)

Current PoP ended Dec 31, 2024 (639 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Bonuses end Sept 30

Want the durability read on 15F06724F0001366? One Pursuit Analysis, $500, inside 48 business hours.

48 business hours
$500
Credits toward the Pack

Buy one Pursuit Analysis — $500

Incumbent footprint

Public record

Glaxosmithkline LLC — $3.0B obligated across 194 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).

% of firm-wide obligated ($3.0B) · all agencies

Department of Health and Human Services (HHS)$3.0B · 100%Department of Defense (DOD)$1.7M · 0%Department of Veterans Affairs (VA)$1.5M · 0%Department of State (DOS)$1.2M · 0%

Open full company profile →

Related awards

Same parent · incumbent

75A50126F61020

TWO-WAY IMMUNOGENICITY TESTING ON EXISTING CLINICAL TRIAL SERA TO IMMUNOGENICITY SUPERIOR…

$493K

Oct 29, 2026

15F06726F0000234

GSK VACCINES TERMS AND CONDITIONS REMAIN THE SAME - BPA 15F06722A0000187

$105K

Dec 31, 2026

75A50124F61014

THIS TASK ORDER ESTABLISHES SERVICES FOR H5 PANDEMIC READINESS FOR ACQUISITION OF MEDICAL …

$18.4M

Feb 21, 2027

75A50124F61013

THE PURPOSE OF THIS TASK ORDER IS TO ESTABLISH FILL/FINISH ACTIVITIES FOR ADJUVANT (AS03) …

$15.4M

Feb 21, 2027

75A50124F61010

THE PURPOSE OF THIS TASK ORDER IS TO PROCURE STORAGE AND STABILITY FOR ANTIGENS AND ADJUVA…

$40.9M

May 21, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 15F06724F0001366?

15F06724F0001366 (GSK TRAVEL vaccines) is a Division 1200 award with a potential value of $115K, currently held by Glaxosmithkline LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 15F06724F0001366?

Division 1200 awarded 15F06724F0001366 to Glaxosmithkline LLC (potential $115K).

Who is the incumbent on 15F06724F0001366?

Glaxosmithkline LLC is the incumbent with $3.0B across 194 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2024.

When does Glaxosmithkline LLC’s 15F06724F0001366 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2024. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Want the durability read on 15F06724F0001366? One Pursuit Analysis, $500, inside 48 business hours.

One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.

Get the free Exposure Check

No card · under a minute · then the Sprint menu

Buy one Pursuit Analysis — $500

Credits toward the Sprint Pack

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Aug 29, 2024